Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers

A prospective, proof-of-concept pilot study in patients with metastatic cancers (9 types of cancers are studied) treated at the IUCT-O or possibly in other institutions. Eligible patients will be selected and informed of this study during a medical consultation for their cancer by medical oncologists. Then, with the patient's consent and before the start of anti-cancer treatment (whatever the line), a blood sample will be taken to detect DP-circulating cells by 2 different methods of analysis. Each patient will participate in the study for one day. The methods of analysis will be: flow cytometry for all patients and either Parsotix® or CellSearch® depending on the type of cancer. 450 patients will be enrolled in total.

NCT Number	NCT06967961
Lead Sponsor	Institut Claudius Regaud
Conditions	Urothelial Carcinoma, Renal Cancer, Prostate Adenocarcinoma, Adenocarcinoma of Endometrium, Cutaneous Melanoma, Soft Tissue Sarcoma (STS), Nonseminomatous Germ Cell Tumor, Seminomatous Germ Cell Tumor +2 more
Enrollment	450 participants
Start Date	2025-07-23
Primary Completion	2029-07-23 (estimated)
Study Completion	2029-07-23 (estimated)
Updated on ClinicalTrials.gov	2026-06-15